Osmetech acquired the Opti product line from Roche Diagnostics. Opti is the portable analysis technology for bloodgas and electrolytes measurement. This highly successful analyser has also taken the veterinary world by storm. IDEXX Laboratories Inc (IDXX) have entered into a ten year OEM agreement to provide the customised OPTI analysers to the veterinary field under the brand VetStat.

In September 2004 the company acquired the "OPTIgene" (Genedrive) product from MS this technology will enable OMH a strong entry point into the fastest growing market segment of DNA based diagnostics. A market that is growing at an annual rate of 20% and is currently worth $ 22 bln !

In the latest acquisition 1/7/05 Osmetech acquired Clinical Micro Sensors from Motorola PLC, OMH plans to utilise the eSensor technology coupled with OPTIgene to address the majority of existing and new tests in the genetic diagnostics market. 'CMS's diagnostic tests for cystic fibrosis and CYP450 are closest to commercial launch and OMH believes that these products have significant market potential.

Scroll & Click for Websites & Other LinksRT Mag Wall Street Reporter Interviews JW

Up Coming Events in 2006

CMS CYP450 product Launch!!!!!............................................. 2006

IDEXX critical care platform Launch!!!!!....................................2006/7....much more to follow

Click Here to Track Osmetech's Progress in the "Stocks That Could Double in 2006" Competition

Yaaaawwwwwwwwwn

The lunch time AFX update


LONDON (AFX) - British diagnostics group Osmetech PLC reported widening
losses in the last 8 months of 2005 after buying molecular diagnostics group
Clinical Micro Sensors (CMS) last year.
Osmetech is reporting 8 month results after changing its year end date. In
the 8 months ended Dec 31 pretax losses widened to 5.4 mln stg from a loss of
2.9 mln in the 12 months ended April 30, 2005.
CMS accounted for 2.9 mln stg of the losses, and Osmetech said group loss
will increase this year reflecting a full year's effect of the new business.
The company is due to launch three new products in the next few months, and
chief executive James White told AFX News that profitability should start to
improve as soon as they hit the market.
"We knew when we bought the business we would have to fund some working
capital, but within 6 months we've got a product ready to hit the market place,"
he said in an interview.
Osmetech has two units, critical care, which makes blood gas analysis
machines, and another that is developing molecular diagnostics equipment.
It was the latter division that was strengthened with the acquisition of CMS
last year. Its first test, to detect the gene for Cystic Fibrosis, will be
launched shortly on the new eSensor platform.
A DNA analysing system called Opti Gene and a product line for use on a
Roche AG instrument will follow.
Osmetech hopes smaller hospitals will buy the machines. They allow doctors
to carry out tests on site and more cheaply than sending away samples to a lab.
White said the market for molecular diagnostics is growing fast as more
tests are developed, and the division has the potential to be more profitable.
The distribution network already established for the critical care business
will be utilised to roll out the new products.
The group will also be looking to acquire and develop new tests, such as for
MRSA detection, the CEO added.
In the last 8 months of 2005, sales surged 78 pct to 5.59 mln stg compared
to the same period the previous year. The result was lifted by a
better-than-expected result from Critical Care.
The launch of a new machine for vets helped boost sales in 2005 by 64 pct to
14.79 mln usd. The company is not anticipating the same level of growth from the
division this year, but sales should still increase significantly and
profitability improve, it predicted.
Osmetech shares were trading 3 pence weaker at 22.25 at noon, valuing the
company at 33 mln stg.
amy.brown@afxnews.com
ab/vjt/ab/ra

COPYRIGHT

clueless tw@ts

Its the market that ultimately judges the company by its performance and future outlook. I would absolutely love OMH to rocket and make me some money, but I think people have to be realistic and not to get carried away with the jam tomorrow syndrome.

exactly Hobbsts you only have to view AD VFN message board to see what Ditchpig and Bangersmam post......if anybody is clueless its them. They abuse and ridicule people who dare to have a slightly different opinion to themselves......so what is the point of investor threads if it is not for debate, either positive or negative. i feel quite sorry for them as I have far better things to do than call people clueless ***** and pathetic. The more OMH posts here the better as I am sure Moneyam will not let this site get as abusive as AD VFN. Sorry to say like most things it is a few people that spoil it for the rest of us.

bangersmam,

not shortsighted, just opening up the debate a little. As I have said, I could be persuaded to buy more OMH, but only if I think I can see significant upside, and more than in the many other stocks I am also watching.

Ditchpig,

You'll notice that I don't make personal comments; I'm here to talk about shares. Ten-baggers, preferably.

And I'll thank you for minding your language.

Usual sell off after the results, the small short sighted PI's sell and the big boys buy. I dont think it will be long before an increased holdings RNS comes out.

My guess is that Gartmore have been loading up. Time will tell.

Presumably you were driven out of Bournemouth with pitchforks and flaming torches. Arrrr don't want none of those namby pamby 'omosexual types 'ere.

Actually it was electric cattle prods - the farmers down in Dorset aren't as backward as they're made out to be.

LOL!
arrr don't be messin wiv this ere new fangled lectric. It be witchcraft I'll tell thee.

So its confirmed - Gartmore WERE buying the shares from the likes of the above shortsighted ones.

SAR 3 - Osmetech plc

FORM SAR 3

DISCLOSURE OF ACQUISITIONS

(Rule 3 of The Rules Governing Substantial Acquisitions of Shares)

Name of acquirer Gartmore Investment Management plc

Beneficial owner, if different (Investments managed on a discretionary
from above basis)

Names of any other persons
acting by agreement or
understanding (see SAR 5)

Company dealt in Osmetech plc

Class of voting shares (eg Ordinary GBP0.001
ordinary shares)

Date of acquisition 22nd March 2006

Number of shares acquired 1,700,000

Number of rights over shares
acquired

Nature of rights over shares

Total holding of voting shares 24,084,657 (18.27%)
(and percentage of total voting
shares in issue)

Total holding of rights over
shares (and percentage of total
voting shares in issue)

Combined total holding (and 24,084,657 (18.27%)
percentage) of voting shares and
rights over shares

Casts a different light on it now.

The threads quiet today, i wonder where our most recent contributors might be??

Am sitting comfortably, still holding onto my OMH shares.

I think this thread needed a dose of realism to inject some proper debate about the future direction of the share price. Opposing views should be welcomed provided that nobody conducts personal vendettas just because they dont agree. I personally dont give a toss if someone calls me a tw@t or something similar, but it hardly adds anything meaningful to the debate.

Can only be a good thing that Gartmore have increased their stake.

Can it? State the ble@ding obvious why don't you.
zzzzzzzzzzzzzzzzzzzz
well you've really added a lot haven't you.
zzzzzzzzzzzzzzzzzzzzz

Sorry DITCHPIG, not going to drop to your level, grown-ups only.

bangersmam,

was busy watching VOG, which is what I bought when I sold my OMH. To date I've gained 14% instead of dropping 30%.

Now if you'll excuse me, I have an appointment to get myself fitted for a new white cane . . .

Yes I'm sure that's what you told the judge.

I continue to hold......if you could read english you would see our posts were about your infantile behaviour.....if anybody reads ADVFN they would see you behave the same way on that thread. My posts from now on are directed to serious traders like Hobbst and Soul traders who have objective views.